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Abstract--E-selectin is an inducible endothelial adhesion molecule that binds neutro- 
phils. E-selectin mRNA is not constitutively detectable in the lungs of rats. Intratra- 
cheal injection of LPS induces pulmonary E-selectin mRNA expression at 2-4 h. 
Intratracheal injection of LPS followed at 2 and 4 h by intravenous injection of mouse 
F(ab')2 or F(ab') anti-E-selectin monoclonal antibody inhibits the emigration of neu- 
trophils into the bronchoalveolar space at 6 h by 50-70%. TNF and IL-6 bioactivity 
are not decreased in bronchoalveolar lavage fluid after treatment with anti-E-selectin 
antibody as compared to controls, suggesting that the anti-E-selectin does not affect 
the magnitude of the LPS-initiated cytokine cascade. Intratracheal injection of LPS 
followed at 2 and 4 h by intravenous injection of soluble E-selectin inhibits neutro- 
philic emigration at 6 h by 64 %, suggesting that endogenous soluble E-selectin shed 
from activated endothelium may play a role in the endogenous down-regulation of 
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acute inflammation. E-selectin-mediated adhesion of neutrophils to endothelium 
appears crucial to the full development of the acute inflammation response. 
I N T R O D U C T I O N  
The intratracheal injection of  endotoxin, a lipopolysaccharide (LPS) component 
of  the cell walls of  gram-negative bacteria, up-regulates endogenous interleu- 
kin-1 (IL-1) and tumor necrosis factor (TNF) expression in the lung and results 
in severe local acute inflammation (1). Intratracheal injection of  exogenous 
recombinant IL-1 or TNF also induces acute inflammation in the lung (1). The 
IL-1 receptor antagonist (2), IL-1 soluble receptor (3), and TNF soluble recep- 
tors types I and II (3, 4) have been shown to inhibit LPS-induced acute pul- 
monary inflammation. 
E-selectin is an endothelial cell adhesion molecule that is implicated in the 
intravascular margination of  neutrophils at sites of  acute inflammation (5). 
IL-1 and TNF induce E-selectin expression on endothelial cells in vitro (6, 7) 
and in vivo (8) and are therefore postulated to mediate acute inflammation in 
part via the induction of  E-selectin. E-selectin is a member of  the selectin 
glycoprotein lectin family that includes L-selectin and P-selectin (5). The selec- 
tin family of  membrane proteins is structurally characterized by an extracellular 
region consisting of  a lectin domain adjacent to an epidermal growth factor-like 
domain followed by six complement regulatory protein-like domains (5). 
E-selectin binds to sialyl-Lewis X, a constitutively expressed membrane car- 
bohydrate on circulating neutrophils (9). E-selectin expression on pulmonary 
endothelium has been shown by immunohistochemistry to occur during immune 
complex-mediated acute lung injury in the rat (10). In the same experimental 
model, antibody to E-selectin inhibited acute inflammation (10). 
The purpose of  the present study in rats is to demonstrate: (1) the kinetics 
o f  E-selectin expression in the lung after intravenous and intratracheal injection 
o f  LPS, (2) inhibition of  LPS- and IL-1 initiated acute pulmonary inflammation 
by intravenous injection of  monoclonal antibody to E-selectin, and (3) inhibition 
of  LPS-initiated acute pulmonary inflammation by intravenous injection of  sol- 
uble E-selectin. 
M A T E R I A L S  AND M E T H O D S  
Lewis rats, male, weighing approximately 225 g, either naive or at specified time points after 
the intratracheal injection of S. typhosa lipopolysaccharide (Sigma Chemical Co., St. Louis, Mis- 
souri), were anesthetized with ether to obtain fresh lung tissue for the extraction of total RNA. 
While the heart was still beating, the lungs were removed and placed in petri dishes containing 10 
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ml of 4 M guanidium isothiocyanate, 25 mM HEPES (pH 7.0) and 0.7 #1/8-mercaptoethanol. The 
lungs, in an ice bath, were immediately homogenized for 30 sec with a Tissuemizer tissue homog- 
enizer. The homogenate was centrifuged in a 50-ml conical tube for 10 min at 10,000 rpm at 12~ 
in a Beckman JA-13 rotor. The RNA-containing supernatant was collected and Sarkosyl was added 
to a final concentration of 0.5%. The supernatant was heated at 65~ for 2 min and then ultracen- 
trifuged at 25,000 rpm over a CsC1 gradient for 20 h in a Beckman SW-41 rotor. The RNA pellet 
was resuspended in 10 mM Tris HC1 (pH 7.4), 5 mM Na2-EDTA, 1% SDS at room temperature 
for 1-2 h, extracted with phenol-chloroform-isoamyl alcohol, and precipitated with 1 : 10 vol 3 M 
sodium acetate and 2.5 vol absolute ethanol at - 3 0 ~  overnight. After drying the pellet in a vacuum 
desiccator, the yield and purity of RNA was quantitated by measuring the ratio of the absorbances 
at 260 and 280 nm. Successful isolation of undegraded RNA was monitored by mini-gel electro- 
phoresis in the presence of ethidium bromide and examination of the sharpness of  the 28S and 18S 
ribosomal RNA bands under ultraviolet light. Northern blotting was performed according to standard 
methodology (11) by electrophoretic separation of total RNA (30 #g/lane) in a formaldehyde agarose 
gel followed by blotting of the RNA onto a nylon membrane (Zeta-probe). Rat E-selectin cDNA 
was used to prepare a probe 1333 nucleotides in length (nucleotides 471-1804 obtained by digestion 
with Bam HI and Sph I) radiolabeled with -t~32p by random sequence hexanucleotide priming 
(prime time " C "  biosystem, International Biotechnologies, Inc., New Haven, Connecticut) to a 
specific activity of approximately 109 cpm/#g. After hybridization, the blots were washed at 65~ 
for 15 min, twice with 2 x  SSC and 0.1% SDS and twice with 0 .2x  SSC and 0.1% SDS. 
In experiments to assess the potential antiinflammatory activity of anti-E-selectin antibody, 
male Lewis rats weighing approximately 225 g were anesthetized with ether and injected intratra- 
cheally with 0.5 ml of  endotoxin (S. typhus lipopolysaccharide, Sigma) followed at 2 and 4 h by 
intravenous injections of either saline, mouse monoclonal F(ab')~ or F(ab') anti-human E-selectin 
(clones M4 or A3), or mouse monoclonal F(ab')~ anti-plant sucrose phosphate synthetase (clone 
HH8). Hybridomas producing monoclonal antibodies (clones M4, A3, and HH8) were kindly pro- 
vided by Chris Carron, Debbie Meyer, and Jodi Pegg (Monsanto Cellular and Molecular Biology). 
For anti-E-selectin antibodies, mice were immunized with activated human umbilical vein endo- 
thelial cells and screened using a purified recombinant E-selectin. Monoclonal antibodies were 
purified from ascites fluid by caprylic acid precipitation followed by ammonium sulfate precipitation 
according to the method of Reik et al. (12). F(ab')2 fragments were prepared from mouse ascites 
fluid by digesting purified immunoglobulins overnight with activated papain in 0.1 M sodium 
acet~.~e, pH 5.5, 3 mM EDTA, using a 20:1 ratio of monoclonal antibody to enzyme, according 
to the method of Parham et al. (13). The reaction was stopped by the addition of 30 mM iodoac- 
etamide. For F(ab') production, a low level of cysteine (approximately 10 mM) was present during 
digestion. The digest ( <  100 mg) was chromatographed over a 3-ml bed volume DEAE-cellulose 
column, equilibrated in 5 mM Tris HC1, pH 7.5, to remove the Fc fragments, followed by a 3-ml 
bed volume protein A sepharose column equilibrated in the same buffer in order to remove any 
remaining intact IgG1, followed by chromatography over a 2.5-cm x 46-cm Sephadex G-75 sizing 
column equilibrated in Dulbecco's phosphate-buffered saline without divalent cations (Sigma) in 
order to separate the F(ab')2 from other reaction products. The final column for resolution of F(ab')2 
and F(ab') was a Sephadex G-150 column, 2.5 x 48 cm. 
Soluble recombinant human monomeric E-selectin was prepared by papain digestion to remove 
the Fc portion of a dimeric E-selectin-Fc fusion protein. Recombinant baby hamster kidney (BHK) 
cells producing a chimeric human E-selectin-lgG1 Fc molecule was kindly provided by Lyle E. 
Pegg (Monsanto Cellular and Molecular Biology). The gene, a generous gift of Brian Seed (Mas- 
sachusetts General Hospital, Boston, Massachusetts) had been expressed in BHK cells using the 
herpesvirus VP16 transactivator [P. Hippenmeyer, M. Highkin. High-level stable production of 
recombinant proteins in mammalian cell culture using the herpesvirus VP16 transactivator. Bit- 
technology, 11:1037-1041, 1993]. The recombinant protein was batch adsorbed onto A3 sepharose 
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and eluted in column mode with 3M MgC12, 0.5 M NaCI, pH 6.8. Following dialysis into 0.9% 
NaC1, 25 mM CaC12, the fusion protein was digested with activated papain using a substrate-to- 
enzyme ratio of 70: 1. The reaction was stopped by the addition of 30 mM iodoaceamide, and mono- 
meric E-selectin was purified by chromatography over the protein A sepharose and Sephadex G-150 
sizing columns as described above for the purification of F(ab)' fragments. 
Six hours after injection of intratracheal LPS and intravenous antibodies or soluble E-selectin, 
the rats were sacrificed and bronchoalveolar lavage (BAL) was performed to enumerate the absolute 
number of  neutrophils in the intraalveolar inflammatory exudate as previously described (1). The 
absolute number of neutrophils in the BAL fluid specimens is expressed as the mean + one standard 
deviation of the mean. TNF and IL-6 protein levels in BAL fluid specimens were determined as 
previously described (WEHI 164, subclone 13 bioassay for TNF, B9 bioassay for IL-6) (14). The 
probability value was determined by the t test (Systat, Inc. Evanston, Illinois). 
RESULTS 
E-selectin mRNA is not constitutively detected in the lung (Figure 1). 
Intratracheal injection of LPS (100/~g) causes E-selectin mRNA expression at 
4 and 6 h (Figure 1). Intravenous injection of LPS (100/~g) causes E-selectin 
mRNA expression at 2 h (Figure 1). E-selectin mRNA expression is no longer 
detected at 4 h after intravenous injection of LPS (Figure 1). 
Monoclonal F(ab')2 anti-E-selectin antibody clones A3 and M4, injected 
Hours after Injection of LPS (100 ug) 
Fig. 1. Intravenous injection of LPS (100/~g) causes the rapid and transient expression of pulmonary 
E-selectin mRNA at 2 b. Intratracheal injection of LPS (100/zg) causes a later and more sustained 
expression of pulmonary E-selectin mRNA at 4 and 6 h. 
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in t ravenously  at 2 and 4 h (500 #g  F(ab ')2 at 2 and 4 h) af ter  intratracheal 
inject ion o f  5 tzg LPS,  both significantly inhibit  the emigra t ion  o f  neutrophils  
into B A L  fluid at 6 h by more  than 50% (Table  1). A h igher  dose o f  M4  (1 mg 
F(ab')2 at 2 and 4 h) did not  afford further inhibit ion o f  inf lammat ion (N = 6 
rats with the h igher  dose o f  M4  and N = 6 controls ,  data not  shown).  The  
number  o f  neutrophils  in B A L  fluid is not  decreased by intravenous inject ion o f  
an unrelated monoc lona l  antibody of  the same species and IgG class (HH8)  or  
by bov ine  serum a lbumin (BSA) (Table 1). F(ab ' )  f ragments  o f  ant i -E-select in  
c lone M4  were  as effect ive as F(ab')2 f ragments  in inhibit ing inf lammat ion 
(Table 1). Intratracheal coinject ion o f  LPS  and F(ab ' )  ant i -E-select in  c lone M4 
did not  significantly inhibit  inf lammat ion (data not  shown).  Intratracheal  injec-  
tion o f  IL-1/3 (5 /xg) fo l lowed by intravenous inject ion o f  ant i -E-select in  c lone  
M4 (500 /zg F(ab')2 at 2 and 4 h) significantly inhibits I L - l - i n d u c e d  acute 
inf lammat ion  (Table 2). 
Table 1. Intravenous Injection of Anti-E-Selectin Antibody Clones A3 or M4 Inhibits Acute In- 
flammation Induced by Intratracheal Injection of LPS 
Inhibition 
Injection protocol a N PMN )< 10 6 BAL (%) P-value 
E-Selectin neutralizing antibodies 
LPS IT + saline IV 9 10.2 + 1.6 
LPS IT + A3 F(ab')2 IV 8 5.0 + 0.7 51 <0.001 
LPS IT + saline IV 6 9.4 + 0.6 
LPS IT + M4 F(ab')2 IV 6 3.2 _+ 0.9 66 <0.001 
LPS IT + saline IV 6 9.4 _+ 0.5 
LPS IT + M4 F(ab') IV 6 2.9 + 0.8 69 <0.001 
Negative Controls 
LPS IT + saline IV 6 11.1 + 2.7 
LPS IT + HH8 F(ab'h IV 6 11.0 + 2.3 0 NS 
LPS IT + saline IV 6 9.4 + 0.3 
LPS IT + BSA IV 6 8.9 + 1.1 5 NS 
aIT = intratmcheal; IV = intravenous. 
Table 2. Intravenous Injection of Anti-E-Selectin Antibody Inhibits Acute Inflammation Induced 
by Intratracheal Injection of IL-1 
Inhibition 
Injection protocol N PMN • 106/BAL (%) P value 
IL-1 IT + saline IV 6 13.0 _+ 2.9 
IL-1 IT + M4 F(ab')2 IV 6 4.6 + 1.0 64 <0.001 
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Table 3. Intravenous Injection of Anti-E-Selectin Antibody Does Not Alter TNF and IL-6 Activity 
in BAL Fluid after Intratracheal Injection of LPS 
Injection protocol N TNF (pg/ml) IL-6 (pg/ml) 
Saline IT + saline IV 2 < 5 < 5 
LPS IT + saline IV 9 181 + 115 2891 + 1013 
LPS IT + A3 IV 8 228 + 78 3000 + 546 
Table 4. Intravenous Injection of Soluble E-Selectin Inhibits Acute Inflammation Induced by In- 
tratracheal Injection of LPS 
Inhibition 
Injection protocol N PMN • 106/BAL (%) P value 
LPS IT + saline IV 6 11.6 + 2.7 
LPS IT + soluble E-selectin IV 6 4.2 + 1.0 64 <0.001 
Intratracheal LPS-induced TNF and IL-6 bioactivity in BAL fluid are not 
affected by intravenous injection of  antibody to E-selectin (Table 3). 
Soluble E-selectin injected intravenously (500 /zg soluble E-selectin at 2 
and 4 h) after intratracheal injection of  5 /~g LPS significantly inhibits the 
emigration of  neutrophils into BAL fluid at 6 h by 64 % (Table 4). 
D I S C U S S I O N  
The kinetics of  neutrophil influx into the lung are different after intravenous 
and intratracheal injection o f  LPS. After intravenous injection of  100 #g of  LPS, 
neutrophils are rapidly sequestered intravascularly in the lung but do not emi- 
grate into the bronchoalveolar space. After  intratracheal injection of  100 /~g 
LPS, neutrophils emigrate into the bronchoalveolar  space at 2 -4  h. 
The kinetics of  E-selectin mRNA expression in the lung are also different 
after intravenous and intratracheal injection of  LPS. E-selectin expression after 
intravenous injection of  LPS occurs earlier and more transiently than after intra- 
tracheal injection. In the case of  intravenous injection of  LPS, endothelial cells 
may be postulated to express E-selectin via the action of  circulating IL-1 and 
TNF,  whose serum concentrations are known to be sharply elevated at 1-2 h 
after intravenous injection of  LPS. The expression of  E-selectin at 2 h after 
intravenous injection of  LPS is consistent with the kinetics of  intravascular 
neutrophil sequestration within the lung (15, 16). The possibili ty can also be 
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considered that circulating LPS may directly bind to endothelial cells to stimulate 
E-selectin expression. E-selectin expression occurs at 4-6 h after intratracheal 
injection of LPS and may be postulated to be the result of alveolar macrophage- 
derived IL-1 and TNF. 
Finally, the different kinetics of E-selectin mRNA expression in the lung 
after intravenous and intratracheal injection of LPS are consistent with the dif- 
ferent expression of IL-1 and TNF after intravenous and intratracheal injection 
of LPS. In contrast to the rapid and transient nature of IL-1 and TNF expression 
in serum after intravenous injection of LPS (17, 18), IL-1 and TNF expression 
in the lung and BAL fluid increase 4-6 after intratracheal injection of LPS (1). 
The differing kinetics of IL-1, TNF, and E-selectin expression in the lung after 
intravenous and intratracheal injection of LPS thus correlate well with the dif- 
ferences in the kinetics and anatomic localization of neutrophils in the lung. 
Intratracheal injection of LPS or IL-1/3 followed by intravenous injection 
of two different clones of anti-E-selectin significantly inhibited the emigration 
of neutrophils into BAL fluid by greater than 50 %. Antibody to E-selectin was 
injected intravenously to allow greater access of the antibody to E-selectin 
expressed on the vascular surface of endothelial cells. Both F(ab')2 and F(ab') 
fragments of anti-E-selectin antibody were able to inhibit acute inflammation 
equally effectively. Intratracheal coinjection of LPS and F(ab') anti-E-selectin 
antibody did not inhibit inflammation, a result that may be due to the timing of 
the injection and/or lack of access of the intratracheal injected antibody to the 
vascular surface of endothelial cells expressing E-selectin. F(ab') antibody was 
chosen for intratracheal injection on the assumption that the smaller size of the 
F(ab') fragments would allow for greater diffusion of the antibody from the local 
tissue compartment into the vascular space. Intratracheal injection of antibody 
at 2 and 4 h after intratracheal injection of LPS was not attempted because of 
the technical difficulty of the procedure. 
The observation that TNF and IL-6 bioactivity in BAL fluid are not affected 
by intravenous injection of antibody to E-selectin is of note not only as a con- 
firmation that the LPS-initiated cytokine cascade was equivalent in the experi- 
mental and control groups, but also as an indication that the TNF and IL-6 
activity in the BAL fluid may be largely alveolar macrophage-derived as opposed 
to neutrophil-derived. Since the neutrophil number in the BAL fluid of rats 
receiving anti-E-selectin was decreased by more than 50%, a decrease in TNF 
and IL-6 activity would have been expected if neutrophils contributed substan- 
tially to TNF and IL-6 expression. Neutrophils are described to express many 
cytokines including TNF, IL-1, and IL-6 (19-21). In previous experiments from 
our laboratory in which intratracheal LPS-initiated inflammation was inhibited 
by blockade of IL-1 and TNF (2-4), a dissection of the contributions of neu- 
trophils and alveolar macrophages to TNF and IL-6 expression was not possible. 
Soluble E-selectin is present in the circulation of patients with septic shock 
396 Ulich et ai. 
(22). The experimental observation that recombinant circulating E-selectin can 
suppress acute inflammation suggests that endogenous circulating E-selectin may 
play a role in the endogenous down-regulation of acute inflammation. As endo- 
thelial-bound E-selectin is shed into the circulation during the course of an acute 
inflammatory reaction, a time must exist when some E-selectin in endothelial- 
bound and some is circulating. The ratio of endothelial-bound to circulating 
E-selectin presumably decreases with time. The intravenous administration of 
antibody to E-selectin or of E-selectin antagonists would likely result in inac- 
tivation of both endothelial-bound and circulating E-selectin. Whether any dif- 
ferences in binding rate to endothelial-bound or circulating E-selectin might exist 
is unclear. One can hypothesize that a time point during the inflammatory reac- 
tion exists when more endogenous E-selectin is present in the circulation than 
on endothelial cells. The administration of anti-E-selectin at that time point 
might interfere more with an endogenous mechanism for the down regulation 
of inflammation than with the proinflammatory function of E-selectin. The phar- 
macologic use of anti-E-selectin as an antiinflammatory agent at such a time 
point during the clinical course of an inflammatory disease might even produce 
the undesirable result of aggravating inflammation. On the other hand, the phar- 
macologic use of soluble E-selectin to block neutrophil-bound E-selectin ligand 
would not be complicated by the presence of endogenous circulating E-selectin. 
In conclusion, LPS-initiated release of macrophage-derived IL-1 and TNF 
would appear to induce endothelial cell E-selectin expression to contribute to 
the accumulation of neutrophils during acute inflammation. Antibodies to 
endothelial-bound E-selectin as well as soluble E-selectin may prove beneficial 
for the treatment of inflammation by interfering with the margination of neutro- 
phils to endothelium at sites of acute inflammation. 
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